APR 06, 2021 7:30 AM PDT

Radioactive Antibody Illuminates Fungal Lung Infections

WRITTEN BY: Tara Fernandez


 

An international team of scientists has pioneered a new procedure to diagnose lung disease caused by common mold. In immunocompromised individuals, the condition known as pulmonary aspergillosis can be life-threatening. With this groundbreaking new technology, physicians can detect the fungal disease faster, more precisely, and in a non-invasive manner for the first time.

We constantly breathe in Aspergillus’ air-borne spores, an abundant environmental mold commonly found in soil and decomposing plant material. For healthy individuals, the immune system destroys these spores before they can cause problems.

However, the fungus is an opportunistic pathogen in those with weakened immune systems, such as those battling underlying health conditions or chemotherapy patients. These individuals are at high risk of developing invasive pulmonary aspergillosis, an infection that can progress rapidly and is frequently fatal. This infection has posed a particular problem for COVID-19 patients in ICU—around a third of them end up developing pulmonary aspergillosis.

Positively diagnosing the disease takes a toll on patients. The current diagnostic standard is a highly invasive technique wherein fluid is injected into the lungs via the nose, and this fluid is then tested for the presence of spores.

Researchers at the University of Exeter have developed the next generation of aspergillosis diagnostics: a humanized Aspergillus-specific monoclonal antibody linked to a radiotracer, known as JF5. This antibody is administered into the bloodstream and targets the Aspergillus. It can be imaged using 3-dimensional microscopy techniques. This technique also allows physicians to monitor the performance of front-line antifungal drugs after a positive diagnosis.

This highly innovative and ground-breaking diagnostic technology is a step-change in the way we diagnose this devastating disease of immunocompromised patients, eliminating our current reliance on unpleasant invasive procedures," said Chris Thornton, the research lead.

While JF5 was validated in animal models, the researchers are confident that it will perform effectively in humans. The team is planning on conducting clinical trials to demonstrate JF5’s full clinical potential before commercializing the technology.

 

Sources: News Medical via University of Exeter, Nature Communications.

 


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 29, 2020
Cardiology
Does Physical Activity Help Reduce the Risk of Aneurysms?
DEC 29, 2020
Does Physical Activity Help Reduce the Risk of Aneurysms?
An active lifestyle is a proven way to prevent many types of cardiovascular diseases. The increased blood flow can preve ...
DEC 30, 2020
Clinical & Molecular DX
Of Mice and Men: Deep Learning Transforms Diagnostics
DEC 30, 2020
Of Mice and Men: Deep Learning Transforms Diagnostics
Medical imaging technologies enable physicians to take a peek under the hood, capturing snapshots of the internal organs ...
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
FEB 03, 2021
Immunology
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
FEB 03, 2021
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
Researchers are still studying how long a person can stay immune against COVID-19 following infection. A new study by a ...
APR 03, 2021
Drug Discovery & Development
Why Are Some Cancer Therapeutics Ineffective?
APR 03, 2021
Why Are Some Cancer Therapeutics Ineffective?
Why don’t some cancer therapeutics not work in humans when they were successful in mice? The answer to this questi ...
APR 13, 2021
Cardiology
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
APR 13, 2021
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
Quick and reliable diagnostics are the key to controlling many diseases, including cardiovascular disease. Biomarkers ar ...
Loading Comments...